Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Disitamab Vedotin”

89 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 89 results

Testing effectiveness (Phase 2)UnknownNCT05627414
What this trial is testing

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableLooking for participantsNCT05831878
What this trial is testing

RC48-ADC in HER2-low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RenJi Hospital 36
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Not applicableNot Yet RecruitingNCT06015113
What this trial is testing

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Who this might be right for
Breast Cancer
Xi'an International Medical Center Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07142200
What this trial is testing

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 45
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Large-scale testing (Phase 3)Not Yet RecruitingNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07100184
What this trial is testing

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Who this might be right for
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
Peking University First Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07172217
What this trial is testing

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

Who this might be right for
Recurrent Cervical Cancer
Qilu Hospital of Shandong University 33
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Testing effectiveness (Phase 2)Looking for participantsNCT07093866
What this trial is testing

Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study

Who this might be right for
mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 20
Testing effectiveness (Phase 2)Looking for participantsNCT06540729
What this trial is testing

RC48 in Combination With AK104 and Bevacizumab in OCCC

Who this might be right for
Ovary Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 39
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07498907
What this trial is testing

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Who this might be right for
Upper Tract Urothelial Carcinoma
Peking University First Hospital 192
Testing effectiveness (Phase 2)Looking for participantsNCT07065435
What this trial is testing

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Who this might be right for
HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Testing effectiveness (Phase 2)Looking for participantsNCT06378242
What this trial is testing

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd. 24
Testing effectiveness (Phase 2)Looking for participantsNCT05912816
What this trial is testing

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Who this might be right for
Upper Urinary Tract Urothelial CarcinomaKidney PreservationHER-2 ADC+1 more
RenJi Hospital 20
Not applicableUnknownNCT05540483
What this trial is testing

RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer

Who this might be right for
Biliary Carcinoma
The First Affiliated Hospital with Nanjing Medical University 31
Testing effectiveness (Phase 2)Looking for participantsNCT07311577
What this trial is testing

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

Who this might be right for
Ovarian Cancer MetastaticOvarian Cancer Metastatic Recurrent
Jiangsu Cancer Institute & Hospital 43
Testing effectiveness (Phase 2)Looking for participantsNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 172
Load More Results